PriceTargets.com logo

Microbot Medical - MBOT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 710.94%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.86 As of 04/25/2024 01:00 AM ET
▼ -0.03 (-3.36%)

This chart shows the closing price for MBOT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Microbot Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MBOT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MBOT

Analyst Price Target is $7.00
▲ +710.94% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Microbot Medical in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 710.94% upside from the last price of $0.86.

This chart shows the closing price for MBOT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Microbot Medical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2024HC WainwrightLower TargetBuy ➝ Buy$8.00 ➝ $7.00Low
10/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$8.00Low
5/8/2023HC WainwrightLower Target$20.00 ➝ $8.00Low
8/18/2020HC WainwrightBoost TargetPositive ➝ Buy$19.00 ➝ $20.00Medium
5/20/2020HC WainwrightReiterated RatingBuy$19.00Low
5/1/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $19.00Low
1/13/2020HC WainwrightBoost TargetBuy$12.00 ➝ $26.00High
12/24/2019HC WainwrightReiterated RatingPositive ➝ Buy$10.00 ➝ $12.00High
11/22/2019HC WainwrightReiterated RatingBuy$10.00Low
9/11/2019HC WainwrightReiterated RatingBuy$10.00Medium
8/21/2019HC WainwrightReiterated RatingBuy$10.00Low
7/22/2019HC WainwrightInitiated CoverageBuy$10.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

-0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Microbot Medical logo
Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. In addition, it provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
Read More

Today's Range

Now: $0.86
Low: $0.86
High: $0.91

50 Day Range

MA: $1.16
Low: $0.86
High: $1.34

52 Week Range

Now: $0.86
Low: $0.86
High: $4.37

Volume

68,671 shs

Average Volume

122,649 shs

Market Capitalization

$12.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Microbot Medical?

The following Wall Street analysts have issued stock ratings on Microbot Medical in the last twelve months: HC Wainwright.
View the latest analyst ratings for MBOT.

What is the current price target for Microbot Medical?

1 Wall Street analysts have set twelve-month price targets for Microbot Medical in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 702.3%. HC Wainwright has the highest price target set, predicting MBOT will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Microbot Medical in the next year.
View the latest price targets for MBOT.

What is the current consensus analyst rating for Microbot Medical?

Microbot Medical currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MBOT will outperform the market and that investors should add to their positions of Microbot Medical.
View the latest ratings for MBOT.

What other companies compete with Microbot Medical?

Other companies that are similar to Microbot Medical include Biotricity, NEXGEL, PetVivo, T2 Biosystems and NeuroMetrix. Learn More about companies similar to Microbot Medical.

How do I contact Microbot Medical's investor relations team?

Microbot Medical's physical mailing address is 25 RECREATION PARK DRIVE UNIT 108, HINGHAM MA, 02043. The biotechnology company's listed phone number is (781) 875-3605 and its investor relations email address is [email protected]. The official website for Microbot Medical is www.microbotmedical.com. Learn More about contacing Microbot Medical investor relations.